SCHEMBL5648288

SCHEMBL5648288

CN(C(=O)Oc1ccc(NS(=O)(=O)c2cn(C)cn2)cc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.55
ALDH1A1 P00352 3/20 0.55
MAPK1 P28482 1/20 0.55
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.50
TSHR P16473 1/20 0.50
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
LIPE Q05469 5/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PIK3CG P48736 3/20 0.45
LMNA P02545 2/20 0.44
HTR6 P50406 1/20 0.42
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647727 0.83 KMT2A (0.52) SMN1; SMN2ALDH1A1MEN1KMT2ARAB9A
SCHEMBL18862468 0.78 TSHR (0.68) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL5645854 0.76 FFAR1 (0.61) SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL5653065 0.75 MEN1 (0.49) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL5647463 0.73 MEN1 (0.55) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL5648290 0.72 MEN1 (0.54) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL5649232 0.72 PFKFB3 (0.56) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL5648859 0.72 EDNRA (0.60) MEN1KMT2ATSHRRAB9ANPSR1
SCHEMBL10192089 0.71 TSHR (0.70) SMN1; SMN2ALDH1A1MAPK1KMT2AL3MBTL1
SCHEMBL5648016 0.71 TDP1 (0.57) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL SMN1; SMN2 4233/4885ALDH1A1 1304/4885MAPK1 3193/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL SMN1; SMN2 4133/4885ALDH1A1 1599/4885MAPK1 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.